BACKGROUND: The immune response of patients who have cancer, who may be receiving immunosuppressive therapy, is generally considered to be decreased. This study aimed to evaluate the immune response of cancer patients to the 2009 influenza A (H1N1) vaccine. PATIENTS AND METHODS: We conducted a prospective single site study comparing the immune response after H1N1 vaccination of healthy controls (group A), patients who had solid tumors and were taking myelosuppressive chemotherapy (group B), patients who had solid tumors and were taking nonmyelosuppressive or no treatment (group C), and patients who had hematologic malignancies (group D). RESULTS: At 2-6 weeks after vaccination, seroconversion was observed in 80.0% of group A (95% confidence interval [CI], 65.0%-89.7%), 72.2% of group B (95% CI, 55.9%-84.3%), 87.0% of group C (95% CI, 72.2%-94.7%), and 75.0% of group D (95% CI, 52.8%-89.2%) (p = NS). The geometric mean titer ratio, that is, geometric mean factor increase in antibody titer after vaccination, was 12.6 (95% CI, 7.9-19.9), 12.7 (95% CI, 7.3-22.1), 23.0 (95% CI, 13.9-38.2), and 12.1 (95% CI, 5.3-27.9) (p = NS), and the seroprotection rates were 95.5% (95% CI, 84.0%-99.6%), 79.0% (95% CI, 63.4%-89.2%), 90.5% (95% CI, 77.4%-96.8%), and 90.0% (95% CI, 71%-98.7%) in the corresponding groups (p = NS). Immune responses were robust regardless of malignancy, or time intervals between the use of myelosuppressive or immunosuppressive medications and vaccination. No participants developed clinical H1N1 infection. CONCLUSION: Cancer patients, whether taking myelosuppressive chemotherapy or not, are able to generate an immune response to the H1N1 vaccine similar to that of healthy controls.
BACKGROUND: The immune response of patients who have cancer, who may be receiving immunosuppressive therapy, is generally considered to be decreased. This study aimed to evaluate the immune response of cancerpatients to the 2009 influenza A (H1N1) vaccine. PATIENTS AND METHODS: We conducted a prospective single site study comparing the immune response after H1N1 vaccination of healthy controls (group A), patients who had solid tumors and were taking myelosuppressive chemotherapy (group B), patients who had solid tumors and were taking nonmyelosuppressive or no treatment (group C), and patients who had hematologic malignancies (group D). RESULTS: At 2-6 weeks after vaccination, seroconversion was observed in 80.0% of group A (95% confidence interval [CI], 65.0%-89.7%), 72.2% of group B (95% CI, 55.9%-84.3%), 87.0% of group C (95% CI, 72.2%-94.7%), and 75.0% of group D (95% CI, 52.8%-89.2%) (p = NS). The geometric mean titer ratio, that is, geometric mean factor increase in antibody titer after vaccination, was 12.6 (95% CI, 7.9-19.9), 12.7 (95% CI, 7.3-22.1), 23.0 (95% CI, 13.9-38.2), and 12.1 (95% CI, 5.3-27.9) (p = NS), and the seroprotection rates were 95.5% (95% CI, 84.0%-99.6%), 79.0% (95% CI, 63.4%-89.2%), 90.5% (95% CI, 77.4%-96.8%), and 90.0% (95% CI, 71%-98.7%) in the corresponding groups (p = NS). Immune responses were robust regardless of malignancy, or time intervals between the use of myelosuppressive or immunosuppressive medications and vaccination. No participants developed clinical H1N1 infection. CONCLUSION:Cancerpatients, whether taking myelosuppressive chemotherapy or not, are able to generate an immune response to the H1N1 vaccine similar to that of healthy controls.
Authors: E Whimbey; L S Elting; R B Couch; W Lo; L Williams; R E Champlin; G P Bodey Journal: Bone Marrow Transplant Date: 1994-04 Impact factor: 5.483
Authors: Ali Alkan; Ebru Karcı; Arzu Yaşar; Gülseren Tuncay; Elif Berna Köksoy; Muslih Ürün; Filiz Çay Şenler; Ahmet Demirkazık; Güngör Utkan; Hakan Akbulut; Yüksel Ürün Journal: Support Care Cancer Date: 2017-03-22 Impact factor: 3.603
Authors: Roy E Strowd; Katrina Swett; Michele Harmon; Annette F Carter; Aurora Pop-Vicas; Michael Chan; Stephen B Tatter; Thomas Ellis; Maria Blevins; Kevin High; Glenn J Lesser Journal: Neuro Oncol Date: 2014-04-08 Impact factor: 12.300
Authors: Dong D Lin; Yunhong Wu; Sudhamshi Toom; Niki Sheth; Kevin Becker; Susan Burdette-Radoux; James D'Silva; Yiwu Huang; Jay Lipshitz; Trishala Meghal; Lan Mo; Pooja Murthy; Philip Rubin; Vijaya Natarajan; Bernadine Donahue; Yiqing Xu Journal: Front Med (Lausanne) Date: 2021-02-16
Authors: Roy E Strowd; Gregory Russell; Fang-Chi Hsu; Annette F Carter; Michael Chan; Stephen B Tatter; Adrian W Laxton; Martha A Alexander-Miller; Kevin High; Glenn J Lesser Journal: Neurooncol Pract Date: 2018-01-06
Authors: Marka R Crittenden; Talicia Savage; Benjamin Cottam; Keith S Bahjat; William L Redmond; Shelly Bambina; Melissa Kasiewicz; Pippa Newell; Andrew M Jackson; Michael J Gough Journal: PLoS One Date: 2013-07-25 Impact factor: 3.240
Authors: Peter Vink; Ignacio Delgado Mingorance; Constanza Maximiano Alonso; Belen Rubio-Viqueira; Kyung Hae Jung; Juan Francisco Rodriguez Moreno; Enrique Grande; David Marrupe Gonzalez; Sarah Lowndes; Javier Puente; Hartmut Kristeleit; David Farrugia; Shelly A McNeil; Laura Campora; Emmanuel Di Paolo; Mohamed El Idrissi; Olivier Godeaux; Marta López-Fauqued; Bruno Salaun; Thomas C Heineman; Lidia Oostvogels Journal: Cancer Date: 2019-02-01 Impact factor: 6.860